Insulet Co. (NASDAQ:PODD) COO Charles Alpuche sold 3,900 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total transaction of $408,642.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ PODD traded down $2.30 on Friday, hitting $103.90. 393,939 shares of the stock traded hands, compared to its average volume of 725,968. Insulet Co. has a 12 month low of $70.80 and a 12 month high of $108.90. The firm has a market cap of $6.21 billion, a price-to-earnings ratio of 2,078.00 and a beta of 1.50. The company has a current ratio of 4.36, a quick ratio of 3.71 and a debt-to-equity ratio of 2.68.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. Insulet had a return on equity of 7.01% and a net margin of 2.37%. The firm had revenue of $159.56 million during the quarter, compared to analyst estimates of $154.66 million. During the same period last year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was up 29.1% on a year-over-year basis. Analysts forecast that Insulet Co. will post 0.26 EPS for the current year.
A number of analysts recently commented on the company. BidaskClub downgraded Insulet from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. BTIG Research raised Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price objective for the company in a report on Monday, May 6th. Northland Securities reissued a “buy” rating and set a $100.00 price objective on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity increased their price objective on Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Finally, Oppenheimer set a $100.00 price objective on Insulet and gave the company a “hold” rating in a report on Tuesday, February 26th. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $105.18.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Recommended Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.